ID
31381
Description
Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin
Keywords
Versions (2)
- 7/31/18 7/31/18 -
- 8/18/18 8/18/18 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 18, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593
Actual administered mCi Dose
- StudyEvent: ODM
Description
Therapeutic Dose
Alias
- UMLS CUI-1
- C0087111
- UMLS CUI-2
- C0178602
Description
Date Therapeutic Dose administered
Data type
date
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C0178602
- UMLS CUI [1,3]
- C0011008
Description
Actual Iodine-131 Anti-B1 Antibody dose administered
Data type
text
Measurement units
- mCi
Alias
- UMLS CUI [1,1]
- C0768182
- UMLS CUI [1,2]
- C3174092
Description
Administrative
Alias
- UMLS CUI-1
- C1320722
Similar models
Actual administered mCi Dose
- StudyEvent: ODM
C0011008 (UMLS CUI [1,2])
C3174092 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C3174092 (UMLS CUI [1,2])